LR-HEALTH-&-BEAUTY
18.6.2020 17:49:09 CEST | Business Wire | Press release
Today, the LR LIFETAKT NIGHT MASTER product was awarded the German Brand Award 2020. This is a sensational success for the LR Health & Beauty company, which launched a new segment in its health portfolio with this sleep drink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005674/en/
In the “Excellent Brands” competition, the vegan, holistically designed product impressed the jury in the “Health & Pharmaceuticals” category as one of the best product brands in the industry. The nightcap also received a “Special Mention” in the cross-industry category “Product Brand of the Year”, in which the jury awards a prize for special aspects of brand management. The German Brand Institute already distinguished LR as a winner in 2019 in the “Beauty & Care” category for its 5in1 Beauty Elixir product.
“The second award in a row for an advanced product development makes me and makes us all, incredibly proud and happy, and highlights our expertise in the health field,” says Andreas Friesch, CEO of LR Health & Beauty. “True to the company motto ‘More quality for your life’, we have developed a natural, effective, non-addictive product that is in touch with today’s trends*. Receiving recognition for this motivates us to keep developing innovative product solutions in the future,” Friesch says.
The secret of healthy sleep: LR LIFETAKT NIGHT MASTER
Healthy sleep improves quality of life, strengthens the immune system and heightens performance. Sleep is a desperate challenge for many but it does not have to be.*
The NIGHT MASTER sleep drink from LR LIFETAKT is an effective dietary supplement that ensures a restful sleep over the long term, in a healthy way that is non-addictive. Natural and scientifically proven active ingredients like hops and saffron extract, aloe vera, the amino acid L-tryptophan, magnesium and zinc, as well as a vitamin B complex distinguish the highly bioavailable formula. With its threefold effect, the product promotes relaxation when falling asleep and relaxation while sleeping through the night, as well as optimized regeneration. The product is vegan and it is gluten, lactose and sugar free. www.LRNightMaster.com
German Brand Award | German Design Council
The German Brand Award is a competition presented by the German Brand Institute. The Institute was founded by the German Design Council (Rat für Formgebung) in order to strengthen brand management as a crucial factor for success in companies in the national and international competitive field. It is a driving force of German brand economy, bringing together major brand-builders and stimulating brand dialog. The German Brand Award presented by the Institute is one of the most notable German brand awards.
The German Design Council is an independent and internationally active institution that supports companies in efficiently communicating design and brand competence, while at the same time aiming to strengthen design awareness among the general public. More information at: german-brand-award.com
LR Health & Beauty
Under the motto “More quality for your life”, the LR Group of Companies, with headquarters in the German city of Ahlen, markets diverse beauty and health products in 28 different countries. These include skin care and color cosmetics, dietary supplements and fragrances. LR Health & Beauty has made it its goal to improve the well-being and health of people through its product portfolio. That is why the company keeps developing new products – from the forces of nature combined with the latest scientific discoveries. Aloe Vera has been one of LR's key competences for over 18 years, where we only use the precious leaf fillet is used. With approximately 1,200 employees and thousands of registered sales partners and customers, LR is one of the leading direct sales companies in Europe. The company has been assisting children in need and their families in various countries around the world through the LR Global Kids Fund e.V. – in a fast and non-bureaucratic way in cooperation with local established institutions.
*78% of Germans suffer from sleep problems, according to a nationwide CATI-representative survey conducted by Mente>factum on behalf of LR in 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005674/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom